11/14
04:18 pm
abus
Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Low
Report
Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
11/14
03:55 pm
abus
Rating for ABUS
Low
Report
Rating for ABUS